Avidity of anti- beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome

Antibodies against beta 2-glycoprotein I (anti- beta 2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidit...

Full description

Saved in:
Bibliographic Details
Published inLupus Vol. 21; no. 7; pp. 764 - 765
Main Authors Cucnik, S, Kveder, T, Artenjak, A, Gallova, Z Ulcova, Swadzba, J, Musial, J, Iwaniec, T, Stojanovich, L, Alessandri, C, Valesini, G, Avcin, T, Tervaert, JW Cohen, Rozman, B, Bozic, B
Format Journal Article
LanguageEnglish
Published 01.06.2012
Subjects
Antibodies
antiphospholipid syndrome
Avidity
beta 2-Glycoprotein I
Epitopes
Systemic lupus erythematosus
Thrombosis
Online AccessGet full text

Cover

More Information
Summary:Antibodies against beta 2-glycoprotein I (anti- beta 2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti- beta 2GPI antibodies. Our results confirmed that high avidity anti- beta 2GPI are associated with thrombosis and APS, while in low avidity anti- beta 2GPI group non-APS (predominantly systemic Lupus erythematosus) patients prevailed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0961-2033
DOI:10.1177/0961203312440057